DK1311286T3 - Behandling af hepatitis C med thymosin og pegyleret interferon - Google Patents

Behandling af hepatitis C med thymosin og pegyleret interferon

Info

Publication number
DK1311286T3
DK1311286T3 DK01966667T DK01966667T DK1311286T3 DK 1311286 T3 DK1311286 T3 DK 1311286T3 DK 01966667 T DK01966667 T DK 01966667T DK 01966667 T DK01966667 T DK 01966667T DK 1311286 T3 DK1311286 T3 DK 1311286T3
Authority
DK
Denmark
Prior art keywords
hepatitis
thymosin
pegylated interferon
treatment
effective amount
Prior art date
Application number
DK01966667T
Other languages
English (en)
Inventor
Alfred R Rudolph
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1311286T3 publication Critical patent/DK1311286T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01966667T 2000-08-07 2001-08-06 Behandling af hepatitis C med thymosin og pegyleret interferon DK1311286T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22331200P 2000-08-07 2000-08-07

Publications (1)

Publication Number Publication Date
DK1311286T3 true DK1311286T3 (da) 2006-10-30

Family

ID=22835968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01966667T DK1311286T3 (da) 2000-08-07 2001-08-06 Behandling af hepatitis C med thymosin og pegyleret interferon

Country Status (12)

Country Link
EP (1) EP1311286B1 (da)
CN (1) CN1461221A (da)
AT (1) ATE332704T1 (da)
AU (2) AU8716001A (da)
CA (1) CA2418154A1 (da)
CY (1) CY1105657T1 (da)
DE (1) DE60121449T2 (da)
DK (1) DK1311286T3 (da)
ES (1) ES2267810T3 (da)
HK (1) HK1056117A1 (da)
PT (1) PT1311286E (da)
WO (1) WO2002011754A1 (da)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy

Also Published As

Publication number Publication date
ATE332704T1 (de) 2006-08-15
WO2002011754A1 (en) 2002-02-14
DE60121449D1 (de) 2006-08-24
CY1105657T1 (el) 2010-12-22
EP1311286B1 (en) 2006-07-12
CN1461221A (zh) 2003-12-10
EP1311286A1 (en) 2003-05-21
PT1311286E (pt) 2006-11-30
AU8716001A (en) 2002-02-18
AU2001287160B2 (en) 2005-08-18
ES2267810T3 (es) 2007-03-16
CA2418154A1 (en) 2002-02-14
DE60121449T2 (de) 2007-02-01
EP1311286A4 (en) 2004-01-28
HK1056117A1 (en) 2004-02-06

Similar Documents

Publication Publication Date Title
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
PL1778272T3 (pl) Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)
NO20025627D0 (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
AR023541A1 (es) Terapia de combinacion para vhc
EA200401525A1 (ru) Способы лечения гепатита (варианты )
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
MD990258A (en) Method of treatment of the acute viral hepatitis B
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
FI954127A (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
MXPA05007901A (es) Terapia de combinacion para hcv.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
PT1150981E (pt) Composto nucleosidico terapeutico
RU99125410A (ru) Способ лечения хронических вирусных гепатитов
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica
MXPA05008425A (es) Metodo de tratamiento con nelfinavir.
RU2003115786A (ru) Способ лечения пневмонии у новорожденных